Accelerating progress in induced pluripotent stem cell research for neurological diseases

Daisuke Ito, Hideyuki Okano, Norihiro Suzuki

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

In 2006, Yamanaka's group pioneered a method for reprogramming somatic cells by introducing definite transcription factors, which enabled the generation of induced pluripotent stem cells (iPSCs) with pluripotency comparable to that of embryonic stem cells. These iPSCs are attracting considerable attention for their potential in rejection-tolerance personalized replacement therapy. In recent years, patient-derived iPSCs have been used to recapitulate the phenotypes of neurological diseases and broaden our understanding of the pathogenesis of many neurological diseases, including those of late onset. It is now expected that iPSCs will serve as an unlimited source of disease-specific neural cells for use in disease modeling. This review outlines current progress in neurodegenerative disease research involving iPSCs and discusses the potential roles iPSCs may play in helping researchers elucidate the pathological processes of neurodegenerative diseases and in drug discovery and regenerative medicine.

Original languageEnglish
Pages (from-to)167-174
Number of pages8
JournalAnnals of Neurology
Volume72
Issue number2
DOIs
Publication statusPublished - 2012 Aug

Fingerprint

Stem Cell Research
Induced Pluripotent Stem Cells
Neurodegenerative Diseases
Regenerative Medicine
Pathologic Processes
Drug Discovery
Embryonic Stem Cells
Transcription Factors
Research Personnel
Phenotype
Research

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

Accelerating progress in induced pluripotent stem cell research for neurological diseases. / Ito, Daisuke; Okano, Hideyuki; Suzuki, Norihiro.

In: Annals of Neurology, Vol. 72, No. 2, 08.2012, p. 167-174.

Research output: Contribution to journalArticle

@article{8a23fd403df544499999c327b632bad8,
title = "Accelerating progress in induced pluripotent stem cell research for neurological diseases",
abstract = "In 2006, Yamanaka's group pioneered a method for reprogramming somatic cells by introducing definite transcription factors, which enabled the generation of induced pluripotent stem cells (iPSCs) with pluripotency comparable to that of embryonic stem cells. These iPSCs are attracting considerable attention for their potential in rejection-tolerance personalized replacement therapy. In recent years, patient-derived iPSCs have been used to recapitulate the phenotypes of neurological diseases and broaden our understanding of the pathogenesis of many neurological diseases, including those of late onset. It is now expected that iPSCs will serve as an unlimited source of disease-specific neural cells for use in disease modeling. This review outlines current progress in neurodegenerative disease research involving iPSCs and discusses the potential roles iPSCs may play in helping researchers elucidate the pathological processes of neurodegenerative diseases and in drug discovery and regenerative medicine.",
author = "Daisuke Ito and Hideyuki Okano and Norihiro Suzuki",
year = "2012",
month = "8",
doi = "10.1002/ana.23596",
language = "English",
volume = "72",
pages = "167--174",
journal = "Annals of Neurology",
issn = "0364-5134",
publisher = "John Wiley and Sons Inc.",
number = "2",

}

TY - JOUR

T1 - Accelerating progress in induced pluripotent stem cell research for neurological diseases

AU - Ito, Daisuke

AU - Okano, Hideyuki

AU - Suzuki, Norihiro

PY - 2012/8

Y1 - 2012/8

N2 - In 2006, Yamanaka's group pioneered a method for reprogramming somatic cells by introducing definite transcription factors, which enabled the generation of induced pluripotent stem cells (iPSCs) with pluripotency comparable to that of embryonic stem cells. These iPSCs are attracting considerable attention for their potential in rejection-tolerance personalized replacement therapy. In recent years, patient-derived iPSCs have been used to recapitulate the phenotypes of neurological diseases and broaden our understanding of the pathogenesis of many neurological diseases, including those of late onset. It is now expected that iPSCs will serve as an unlimited source of disease-specific neural cells for use in disease modeling. This review outlines current progress in neurodegenerative disease research involving iPSCs and discusses the potential roles iPSCs may play in helping researchers elucidate the pathological processes of neurodegenerative diseases and in drug discovery and regenerative medicine.

AB - In 2006, Yamanaka's group pioneered a method for reprogramming somatic cells by introducing definite transcription factors, which enabled the generation of induced pluripotent stem cells (iPSCs) with pluripotency comparable to that of embryonic stem cells. These iPSCs are attracting considerable attention for their potential in rejection-tolerance personalized replacement therapy. In recent years, patient-derived iPSCs have been used to recapitulate the phenotypes of neurological diseases and broaden our understanding of the pathogenesis of many neurological diseases, including those of late onset. It is now expected that iPSCs will serve as an unlimited source of disease-specific neural cells for use in disease modeling. This review outlines current progress in neurodegenerative disease research involving iPSCs and discusses the potential roles iPSCs may play in helping researchers elucidate the pathological processes of neurodegenerative diseases and in drug discovery and regenerative medicine.

UR - http://www.scopus.com/inward/record.url?scp=84865612436&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865612436&partnerID=8YFLogxK

U2 - 10.1002/ana.23596

DO - 10.1002/ana.23596

M3 - Article

VL - 72

SP - 167

EP - 174

JO - Annals of Neurology

JF - Annals of Neurology

SN - 0364-5134

IS - 2

ER -